Brett Hart - AbbVie Independent Director
| ABBV34 Stock | BRL 51.60 0.35 0.68% |
Director
Mr. Brett J. Hart is an Independent Director of the company. Mr. Hart is the executive vice president, chief administrative officer and general counsel of United Continental Holdings, Inc. and United Airlines, Inc., a position he has held since May 2017. He served as executive vice president and general counsel between February 2012 and May 2017. Mr. Hart also served as acting chief executive officer of UAL and United Airlines, Inc. from October 2015 to March 2016. From December 2010 to February 2012, he served as senior vice president, general counsel and secretary of UAL, United and Continental. From June 2009 to December 2010, Mr. Hart served as executive vice president, general counsel and corporate secretary at Sara Lee Corporationrationration. since 2016.
| Age | 48 |
| Tenure | 8 years |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0927 % which means that it generated a profit of $0.0927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7529 %, meaning that it generated $0.7529 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Flavio Cesar | Telecomunicaes Brasileiras SA | N/A | |
| Demi Getschko | Telecomunicaes Brasileiras SA | N/A | |
| Sharon Garrett | Ross Stores | 69 | |
| Helio Graciosa | Telecomunicaes Brasileiras SA | N/A | |
| Flavio Lammel | Telecomunicaes Brasileiras SA | N/A | |
| Silvinio Bento | Telecomunicaes Brasileiras SA | N/A | |
| Jose Oliveira | Telecomunicaes Brasileiras SA | N/A | |
| Renato Vieira | Telecomunicaes Brasileiras SA | N/A | |
| Gunnar Bjorklund | Ross Stores | 59 | |
| Lawrence Peiros | Ross Stores | 61 | |
| Marcelo Freitas | Telecomunicaes Brasileiras SA | N/A | |
| Marcio Campello | Telecomunicaes Brasileiras SA | N/A | |
| Jarbas Valente | Telecomunicaes Brasileiras SA | N/A | |
| George Orban | Ross Stores | 72 | |
| Alex Magalhaes | Telecomunicaes Brasileiras SA | N/A | |
| Antonio Salgado | Telecomunicaes Brasileiras SA | N/A | |
| Rafael Rocha | Telecomunicaes Brasileiras SA | N/A | |
| Alfonso Orlandi | Telecomunicaes Brasileiras SA | N/A | |
| Gregory Quesnel | Ross Stores | 69 | |
| Stephen Milligan | Ross Stores | 54 | |
| Michael Bush | Ross Stores | 57 | |
Management Performance
| Return On Equity | 0.75 | |||
| Return On Asset | 0.0927 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carlos Alban, Executive Vice President - Commercial Operations | ||
| Robert Michael, Vice President Controller | ||
| Jeffrey Stewart, Senior Vice President U.S. Commercial Operations | ||
| Brett Hart, Independent Director | ||
| William Chase, Executive Vice President CFO | ||
| Roxanne Austin, Independent Director | ||
| Perry Siatis, Gen VP | ||
| Azita SalekiGerhardt, Senior Vice President - Operations | ||
| Scott Reents, VP CFO | ||
| Edward Rapp, Independent Director | ||
| Richard Gonzalez, Chairman of the Board, CEO | ||
| Brian Durkin, Vice President Controller | ||
| Frederick Waddell, Independent Director | ||
| Robert Alpern, Independent Director | ||
| Thomas Hudson, VP Officer | ||
| Glenn Tilton, Lead Independent Director | ||
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
| Elizabeth Shea, VP Relations | ||
| Rebecca Roberts, Independent Director | ||
| Edward Liddy, Independent Director | ||
| William Burnside, Independent Director | ||
| Timothy Richmond, Senior Vice President - Human Resources | ||
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
| Laura Schumacher, Executive Vice President External Affairs, General Counsel and Corporate Secretary | ||
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
| Melody Meyer, Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.75 | |||
| Return On Asset | 0.0927 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 1.85 T | |||
| Shares Outstanding | 28.3 B | |||
| Price To Earning | 92.88 X | |||
| Price To Book | 18.25 X | |||
| Price To Sales | 26.35 X | |||
| Revenue | 58.05 B |
Pair Trading with AbbVie
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AbbVie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AbbVie will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to AbbVie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AbbVie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AbbVie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AbbVie Inc to buy it.
The correlation of AbbVie is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AbbVie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AbbVie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AbbVie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |